drugset
drugset / Trial / NCT00116376

Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)

NCT00116376 ↗

Phase 1/2 Completed 64 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against the ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will assess the safety, pharmacokinetic/pharmacodynamic (PK/PD) profiles and clinical activity of AEE788 in a recurrent GBM population.

Timeline

Start
2004-01
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AEE788 Small molecule — Oral

Indications

glioblastoma